HALO · Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided an update on its recent corporate activities. "2025 was a pivotal year for Halozyme as we delivered record total revenue of $1.4 billion, which was the result of continued growth in our ENHANZE business. In addition, we expanded our drug delivery technology portfolio with two acquisitions. Three ENHANZE‑enabled blockbusters, DARZALEX SC, Phesgo and VYVGART Hytrulo, drove royalty revenue growth of 52%, reaching a record $868 million in 2025. In the year, we also expanded our ENHANZE opportunities, adding three new collaboration and licensing agreements with Takeda, Merus and Skye Bioscience and gained one new target nomination from Roche. Furthermore, Janssen expanded the global reach of ENHANZE with approvals in the U.S., China and Japan for Rybrevant SC and new indication approvals in

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading. Halozyme will host a conference call on Tuesday, February 17, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/624893800?pwd=q3lpEa6F A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com . About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE ® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today provided a business update, including providing preliminary unaudited 2025 revenue estimates and raising full year 2026 and multi-year financial guidance. The Company also announced it acquired Surf Bio, Inc. ("Surf Bio"), a biopharmaceutical company with an innovative, biologic hyperconcentration technology seeking to transform the delivery of antibodies and biologics, in December 2025. "Our increased multi-year guidance reflects both the strength of our core ENHANZE business and the exceptional momentum we built in 2025. In 2025, we expect royalty revenue growth to exceed 50% year‑over‑year, a clear demonstration of the strength of our business model and the durable demand for ENHANZE‑enabled products globally. In parallel, we significantly expanded new partnerships, signing three new ENHANZE collaboration and licensing agreements, one new auto-injector commercial licensing and supply agreement and two

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT / 8:30 am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and a business update. Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I1205969 . The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and presentation materials, which will be available 15 minutes before the call, please visit Halozyme.com . About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established

Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive license agreement with Takeda in December 2025. The agreement provides Takeda with access to Halozyme's ENHANZE ® drug delivery technology, the leading proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20), for use with vedolizumab. Vedolizumab is marketed globally as ENTYVIO. "Our collaboration with Takeda reflects our ongoing commitment to delivering innovative solutions that enhance the patient experience, with the goal of helping patients spend less time managing their therapy and more time living their lives," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "Our new collaboration reinforces the broad applicability and value of the ENHANZE technology across multiple therapeutic areas." "People living with ulcerative colitis and Crohn's disease, as well as their health care providers, need flexible treatment options that

Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global collaboration and license agreement in December 2025. Under the collaboration, Skye has licensed Halozyme's ENHANZE ® drug delivery technology for the development and potential commercialization of a subcutaneous formulation of nimacimab for the treatment of obesity. The collaboration is intended to support Skye's evaluation of higher nimacimab subcutaneous doses through delivery of larger injection volumes. "Our collaboration with Skye Bioscience expands the reach of our ENHANZE technology into the growing obesity market, a therapeutic area with significant long-term potential," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "This agreement reinforces the scalability of ENHANZE across diverse indications and supports our strategy to drive sustainable royalty growth with new partnerships and innovations." "To